BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22442350)

  • 21. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
    Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
    Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
    Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.
    Ma SY; Lie AK; Au WY; Chim CS; Kwong YL; Liang R
    Hong Kong Med J; 2004 Apr; 10(2):77-83. PubMed ID: 15075426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.
    Georges GE; Maris MB; Maloney DG; Sandmaier BM; Sorror ML; Shizuru JA; Lange T; Agura ED; Bruno B; McSweeney PA; Pulsipher MA; Chauncey TR; Mielcarek M; Storer BE; Storb R
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):423-32. PubMed ID: 17287157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D
    Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.
    Peters C; Schrappe M; von Stackelberg A; Schrauder A; Bader P; Ebell W; Lang P; Sykora KW; Schrum J; Kremens B; Ehlert K; Albert MH; Meisel R; Matthes-Martin S; Gungor T; Holter W; Strahm B; Gruhn B; Schulz A; Woessmann W; Poetschger U; Zimmermann M; Klingebiel T
    J Clin Oncol; 2015 Apr; 33(11):1265-74. PubMed ID: 25753432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
    Kawamura K; Tsukada N; Kanda Y; Ikeda T; Yoshida A; Ueda Y; Ishida T; Suzuki K; Murakami H
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1392-1398. PubMed ID: 29555314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
    Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.
    Montefusco V; Mussetti A; Rezzonico F; Maura F; Pennisi M; de Philippis C; Capecchi M; Corradini P
    Bone Marrow Transplant; 2017 Dec; 52(12):1602-1608. PubMed ID: 28892086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.
    Giaccone L; Storer B; Patriarca F; Rotta M; Sorasio R; Allione B; Carnevale-Schianca F; Festuccia M; Brunello L; Omedè P; Bringhen S; Aglietta M; Levis A; Mordini N; Gallamini A; Fanin R; Massaia M; Palumbo A; Ciccone G; Storb R; Gooley TA; Boccadoro M; Bruno B
    Blood; 2011 Jun; 117(24):6721-7. PubMed ID: 21490341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
    Koehne G; Giralt S
    Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
    Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N;
    Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis.
    Castagna L; Mussetti A; Devillier R; Dominietto A; Marcatti M; Milone G; Maura F; de Philippis C; Bruno B; Furst S; Blaise D; Corradini P; Montefusco V
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1549-1554. PubMed ID: 28499937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.
    Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
    Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
    J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma.
    Chen Y; Fu WJ; Xu LP; Ren HY; Lai YR; Liu DH; Liu L; Sun ZM; Wu YB; Wang X; Xia LH; Jiang M; Hu TL; Wan DM; Huang XJ
    Chin Med J (Engl); 2019 Aug; 132(15):1765-1772. PubMed ID: 31306219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.